Shanghai ZJ Bio-Tech CoSHSE:688317 -1.80%65 PS Ratio is 22.21 as of Jun. 30, 2026, which is 242% above its 10-year median of 6.49. GuruFocus rates SHSE:688317 with a GF Score™ of 65/100 and a GF Value™ of ¥9.93 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Shanghai ZJ Bio-Tech Co ranks worse than 91.42% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Shanghai ZJ Bio-Tech Co's share price is ¥15.28.
Shanghai ZJ Bio-Tech Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.69. Hence, Shanghai ZJ Bio-Tech Co's PS Ratio for today is 22.21.
Good Sign:
Shanghai ZJ Bio-Tech Co Ltd stock PS Ratio (=21.93) is close to 1-year low of 21.93.
The historical rank and industry rank for Shanghai ZJ Bio-Tech Co's PS Ratio or its related term are showing as below:
SHSE:688317'
s PS Ratio Range Over the Past 10 Years
Min: 2.59 Med: 6.49 Max: 36.92
Current: 22.21
During the past 13 years, Shanghai ZJ Bio-Tech Co's highest PS Ratio was 36.92. The lowest was 2.59. And the median was 6.49.
SHSE:688317's PS Ratio is ranked worse than 91.42% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.87
vs SHSE:688317: 22.21
Shanghai ZJ Bio-Tech Co Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Shanghai ZJ Bio-Tech Co was -17.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -61.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -50.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 3.80% per year.
During the past 13 years, Shanghai ZJ Bio-Tech Co's highest 3-Year average Revenue per Share Growth Rate was 120.60% per year. The lowest was -61.40% per year. And the median was 5.45% per year.
Back to Basics: PS Ratio
Shanghai ZJ Bio-Tech Co (SHSE:688317) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai ZJ Bio-Tech Co PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Shanghai ZJ Bio-Tech Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Shanghai ZJ Bio-Tech Co's Share Price of today is ¥15.28. Shanghai ZJ Bio-Tech Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.69.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a PS Ratio of 22.21 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. This is 242% above median its historical median of 6.49. Over the past decade, Shanghai ZJ Bio-Tech Co's PS Ratio has ranged from 2.59 to 36.92. According to the industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #735 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 91.4%.
Is Shanghai ZJ Bio-Tech Co's PS Ratio too high?
Shanghai ZJ Bio-Tech Co's current PS Ratio of 22.21 is 242% above median its 10-year median of 6.49. Over the past 10 years, this metric has ranged from a low of 2.59 to a high of 36.92. The Medical Devices & Instruments industry median PS Ratio is 2.87. Shanghai ZJ Bio-Tech Co's value of 22.21 is 673.9% above this industry median. Based on the distribution chart, Shanghai ZJ Bio-Tech Co ranks #735 out of 804 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #735 out of 804 companies for PS Ratio. This places Shanghai ZJ Bio-Tech Co in the lower half of its industry. The industry median PS Ratio is 2.87. Shanghai ZJ Bio-Tech Co's value of 22.21 is 673.9% above this benchmark. Historically, Shanghai ZJ Bio-Tech Co's own PS Ratio has ranged from 2.59 to 36.92 over the past decade. While the company's 10-year median is 6.49 vs. the industry median of 2.87, Shanghai ZJ Bio-Tech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.87, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai ZJ Bio-Tech Co's current PS Ratio of 22.21 is 673.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai ZJ Bio-Tech Co's current PS Ratio is 22.21, which is 242% above median its own 10-year median of 6.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.93, compared to a current price of ¥15.28 — trading 53.9% above its estimated fair value. The current PS Ratio is 22.21, which is 242% above median its 10-year median of 6.49 and 673.9% above the Medical Devices & Instruments industry median of 2.87. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current PS Ratio is 22.21 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued.
The current stock price of ¥15.28 is trading 53.9% above its estimated GF Value™ of ¥9.93.
GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688317:
PS Ratio: 22.21 (242% above median its 10-year median of 6.49)
GF Value™: ¥9.93 vs. price of ¥15.28 (53.9% above fair value)
Industry Position: 673.9% above the Medical Devices & Instruments median (#735 of 804)
No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
65GF Score
Get the complete analysis for SHSE:688317
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688317 has been successfully added to your 
